CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1573495
This article is part of the Research TopicAdvances in skin immunologyView all 9 articles
Guselkumab Treatment for Sintilimab-Exacerbated Psoriasis in a Cancer Patient: A Case Report
Provisionally accepted
- Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. Psoriatic lesions are typically characterized by sharply demarcated, erythematous plaques with silvery scales. Treatment options include topical agents, phototherapy, systemic therapies, and biologic agents. Traditional systemic treatments used are generally contraindicated in patients with cancer due to their immunosuppressive effects. Although biologics are widely used in psoriasis management, their safety in patients with malignancy remains inadequately evaluated because individuals with cancer are typically excluded from clinical trials, owing to concerns about cancer progression. We report the case of a 61-year-old male with psoriasis that markedly worsened following treatment with sintilimab for pulmonary metastases secondary to colon cancer. The patient was successfully treated with guselkumab, an interleukin (IL)-23 inhibitor, which led to significant improvement in psoriasis symptoms, while the patient's pulmonary condition remained stable during follow-up after completion of standard cancer therapy. This case highlights the potential utility of IL-23 inhibitors as safe and effective treatment options for patients with concomitant psoriasis and malignancy.
Keywords: immune checkpoint therapy, Cutaneous adverse effects, Psoriasis, biologics, Cancer
Received: 09 Feb 2025; Accepted: 30 May 2025.
Copyright: © 2025 Ke, Guo, Zhao, Liu, Meng and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qinqin Meng, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
Hui Deng, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.